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The mechanisms that regulate the transition between
the initial priming phase and DNA replication in liver
regeneration are poorly understood. To study this tran-
sition, we compared events occurring after standard
two-thirds partial hepatectomy, which elicits full regen-
eration, with response to a reduced hepatectomy, one-
third partial hepatectomy (1/3PH), which leads to little
DNA replication. Although the initial response to partial
hepatectomy at the priming phase appeared to be simi-
lar between the two procedures, cell cycle progression
was significantly blunted in 1/3PH mice. Among the
main defects observed in 1/3PH mice were an almost
complete deficiency in retinoblastoma phosphorylation
and the lack of increase in kinase activity associated
with cyclin E. We report that, in two-thirds partial hep-
atectomy mice, the expression of heparin-binding epi-
dermal growth factor-like growth factor (HB-EGF) pre-
ceded the start of DNA replication and was not
detectable in 1/3PH animals. Injection of HB-EGF into
1/3PH mice resulted in a >15-fold increase in DNA rep-
lication. Moreover, we show that hepatocyte DNA repli-
cation was delayed in HB-EGF knock-out mice. In sum-
mary, we show that HB-EGF is a key factor for
hepatocyte progression through G1/S transition during
liver regeneration.
Adult hepatocytes, while highly differentiated, retain a re-
markable ability to proliferate in response to liver injury or
reduction in hepatic mass. The surgical removal of 70% of the
liver, two-thirds partial hepatectomy (2/3PH),1 is the most
studied model of liver regeneration. This procedure induces a
synchronized growth response involving almost all hepato-
cytes, leading to the restoration of liver mass in 7–10 days in
rodents (1).
Liver regeneration is a complex process involving the activa-
tion of multiple pathways. The entry of quiescent hepatocytes
into the cell cycle, corresponding to the G0/G1 transition, is
largely regulated by cytokines. This phase, often referred to as
priming, is characterized by the increase in cytokines such as
tumor necrosis factor- and IL-6 and the activation of imme-
diate early genes that include c-jun, c-fos, and c-myc (2). Al-
though this phase is essential for the hepatocyte response to
growth factors, the priming stage is reversible. Without the
involvement of growth factors, hepatocytes do not progress
through cell cycle and they return to quiescence (3).
Hepatocyte growth factor (HGF) and transforming growth
factor- (TGF-) are two of the most studied growth factors in
liver regeneration. It has been demonstrated that the mRNA
levels of both growth factors are elevated after 2/3PH (4, 5).
HGF stimulates hepatocyte replication by paracrine or endo-
crine mechanisms (6, 7). Recent studies using conditional
knock-out mice for the HGF receptor, c-Met, showed that c-Met
signaling is essential for liver regeneration and may primarily
affect hepatocyte survival and tissue remodeling (8, 9). By
contrast, TGF- is an autocrine factor whose effects are pri-
marily proliferative (5). However, TGF- knock-out mice have
no defects in liver regeneration, an observation that might be
explained by the redundancy of ligands of the EGF family (10).
Indeed, heparin-binding EGF-like growth factor (HB-EGF) has
been reported to participate in liver regeneration (11), but its
role has not been well characterized. Nevertheless, transgenic
mice expressing HB-EGF appear to have an accelerated liver
growth response after partial hepatectomy (12).
The interaction between the early events of liver regenera-
tion and growth factor availability is crucial for the regenera-
tive process. However, the events linking these two phases
have not been characterized. Bucher and Swaffield (13) show
that the extent of hepatocyte replication in the regenerating
liver of adult rats is proportional to the amount of tissue re-
sected for resections involving 40–70% of the liver (13). Re-
moval of 30% of the liver lies below this threshold and does not
elicit a clear wave of DNA replication. Moreover, we have
previously demonstrated that continuous infusion of TGF- or
HGF for 24 h into the portal vein of rats with 30% hepatecto-
mies or one-third partial hepatectomy (1/3PH) produced a vig-
orous replicative response to the growth factors (14). Together,
these data indicated that 1/3PH, in contrast to the standard
2/3PH, may induce hepatocyte priming that does not progress
to DNA replication. We reasoned that the analysis of events
occurring after 1/3PH may uncover linkages between priming
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and cell cycle progression that are decisive for liver regenera-
tion. Here we show that HB-EGF is a key factor for the pro-
gression of hepatocytes through the G1/S phases.
MATERIALS AND METHODS
Animals and Surgical Procedures—8–10-week-old male wild-type
C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME) were kept on a
12-h light/dark cycle with free access to food and water. HB-EGF-null
male mice were from a hybrid C57BL/6  129/Sv background (15). In
experiments using HB-EGF/ mice, the wild-type controls were from
the same hybrid background. Partial hepatectomies were performed
under general anesthesia with inhaled isofluorane. One-third hepatec-
tomy consisted of ligating the pedicle of the left lateral lobe before
excising it. Two-thirds hepatectomy was performed as described by
Higgins and Anderson (16). Sham surgery consisted of a midline lapa-
rotomy with gentle manipulation of the liver. Surgeries were performed
between 8 a.m. and 4 p.m., and mice were killed at different time points
after surgery as described in the legends of the figures. All of the animal
work was done in accordance with the animal care committees of the
University of Washington and the University of North Carolina at
Chapel Hill.
Growth Factor Injections—For the growth factor experiment, male
wild-type C57BL/6 mice received a bolus injection of 0.1 mg/kg HB-EGF
(R&D Systems, Minneapolis, MN; dissolved in 0.9% NaCl), HGF (a gift
from Genentech, San Francisco, CA; dissolved in 0.5 M NaCl and 20 mM
Tris, pH 7.6), or TGF- (R&D Systems; dissolved in 0.9% NaCl) through
the tail vein 24 h after a one-third partial hepatectomy. Mice were killed
36 h after hepatectomy and 12 h after growth factor injection.
BrdUrd Immunohistochemistry—Mice received an intraperitoneal
injection of BrdUrd (50 mg/kg) (Roche Applied Science) 2 h before
killing. Livers were fixed in methacarn (60% methanol, 30% chloroform,
and 10% acetic acid) overnight at room temperature and then embedded
in paraffin. BrdUrd incorporation was measured using a mouse anti-
BrdUrd antibody (Dako, Carpinteria, CA) and the Elite Vectastain ABC
kit (Vector laboratories, Burlingame, CA) as described previously (17).
For each liver sample, 3,000 hepatocytes were counted.
Western Blot Analyses—Total liver protein was isolated from snap-
frozen tissue by homogenization in immunoprecipitation lysis buffer de-
scribed previously and briefly sonicated (17). Nuclear extracts were pre-
pared as described previously (18). Proteins (30 g for total liver protein
and 10 g for nuclear extracts) were separated on 12% SDS-PAGE (29:1
(v/v) acrylamide:Bis) gels with the exception of phospho-retinoblastoma
(Rb) blots in which 10% (30:0.4 (v/v) acrylamide:Bis) SDS-PAGE gels were
used and TGF- blot in which Tris-Tricine 10–20% gels (Bio-Rad) were
used. Proteins were transferred onto nitrocellulose membranes (Hybond
ECL, Amersham Biosciences) and blocked in 5% milk TBST (Tris-buff-
ered saline with 0.1% Tween 20) prior to incubation with primary anti-
body. The following antibodies were used: cyclin A (sc-596, Santa Cruz
Biotechnology, Santa Cruz, CA); p21 (556431, BD Biosciences); phos-
pho-Rb (Ser-807/811, Cell Signaling, Beverly, MA); cyclin D1 (AHF 082,
BIOSOURCE, Camarillo, CA); cyclin E (06–459, UBI, Lake Placid, NY);
p107 (sc-318, Santa Cruz Biotechnology); TGF- (clone MF9, LabVision,
Fremont, CA); and -actin (A5316, Sigma). Secondary antibodies were
purchased from Amersham Biosciences. Enhanced chemiluminescence
(Western Lightning Chemiluminescence reagent, PerkinElmer Life Sci-
ences) was used for detection.
Immunoprecipitation and Kinase Assay—For cyclin-dependent ki-
nase-4 (Cdk-4) immunoprecipitation, total protein lysates (500 g) were
incubated with 1 g of anti-Cdk-4 antibody (sc-260, Santa Cruz Bio-
technology) overnight at 4 °C. Protein A-Sepharose (Sigma) (30 l of 1:1
(v/v) in lysis buffer) was added for 90 min, and the bound complexes
were washed twice in lysis buffer. Immunoprecipitated proteins were
subsequently resuspended in 2 sample buffer and resolved by 12%
SDS-PAGE. Blotting was performed as described above with cyclin D1
antibody.
For cyclin E/Cdk-2 kinase assay (cyclin E-associated kinase assay),
500 g of liver lysate were incubated with 1 g of anti-cyclin E
antibody 1 h at 4 °C. Protein A-Sepharose (30 l of 1:1 (v/v) in lysis
buffer) was added for 2 h, and the bound complexes were washed
twice in lysis buffer and twice in 1 kinase buffer (3 kinase buffer:
25 mM Tris-HCl, pH 7.5, 70 mM NaCl, 10 mM MgCl2, and 1 mM
dithiothreitol). The beads were resuspended in 10 l of 3 kinase
buffer to which 1.2 g of histone H1, 10 mM ATP, and 6 Ci of
[-32P]ATP (3,000 Ci/mmol, PerkinElmer Life Sciences) were added.
The samples were subsequently incubated at 30 °C for 25 min, and
reactions were terminated by the addition of 2 sample buffer. Sam-
ples were subjected to 12% SDS-PAGE, and 32P-labeled proteins were
quantified by scintillation counting of excised bands.
Ribonuclease Protection Assays (RPA)—Total RNA was extracted
from frozen liver tissue using TRIzol reagent (Invitrogen) as described
by the manufacturer. Total RNA (10 g) was then subjected to the
RiboQuant Multi-Probe ribonuclease protection assay system (BD Bio-
sciences) according to the manufacturer’s specifications. The following
sets of Multi-Probe templates (BD Biosciences) were used: c-myc (num-
ber 556193) and two custom probe sets, A and B. The custom probe set
A included the following mouse DNA templates: c-jun; HGF; p53; c-fos,
HB-EGF; TGF-1; fatty-acid synthase; L32; and glyceraldehyde-3-phos-
phate dehydrogenase. The custom probe set B included the following
templates: tumor necrosis factor-; IL-1; SOCS-3; KC (a cytokine-
induced neutrophil chemoattractant); ICAM (intercellular adhesion
molecule); SOCS-1; IL-6; interferon-; IL-12; L32; and glyceraldehyde-
3-phosphate dehydrogenase. Samples were loaded on a 6% Tris borate-
EDTA/urea gel (Invitrogen) at 150 V for 1.5 h. Gels were subsequently
dried, and signals were quantified using a PhosphorImager. To control
for equal loading between samples, the level of each mRNA species was
normalized against the level of the housekeeping gene transcript, L32.
Real-time Reverse Transcriptase-PCR—One microgram of total RNA
from livers was used for the Reverse Transcriptase reaction using
Applied Biosystems TaqMan reverse transcription kit, and then one-
tenth of the reaction was employed for the real-time PCR analysis.
Assay kits for mouse TGF- and amphiregulin from Applied Biosystems
(Foster City, CA) were used for the quantification of the expression of
these genes in an Applied Biosystems 7900HT SDS instrument. The
housekeeping gene mouse -glucuronidase (Applied Biosystems) was
used to normalize the measurements using the - Ct method. The
PCR conditions were the standard when using TaqMan hydrolysis
probes.
Statistical Analysis—Statistical calculations were performed using
the software Statview 4.5 (SAS Institute, Cary, NC). The Mann-Whit-
ney test and the ANOVA Student’s t test were used. p values lower than
0.05 were accepted as significant. Error bars indicate the mean  S.E.
FIG. 1. Hepatocyte proliferation after one-third or two-thirds
partial hepatectomy. A, DNA synthesis was analyzed by BrdUrd
incorporation at different times after partial hepatectomy (n  3 ani-
mals/group). Sham animals were killed 36 h post-surgery. B, hepato-
cytes undergoing mitosis at 48 h post-partial hepatectomy. The graph
reflects the number of mitotic cells per 3,000 hepatocytes counted per
animal (n  4 animals/group). *, p  0.05; **, p  0.01.
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RESULTS
A Lack of Synchronized DNA Replication after 1/3PH in
Mice—In rats, the removal of 30% of the liver results in little
DNA replication (13, 19). To determine whether 1/3PH also
fails to elicit a wave of hepatocyte replication in mice, we
analyzed DNA replication of hepatocytes after 1/3PH at dif-
ferent times after surgery and compared with DNA replica-
tion after 2/3PH. We observed a striking difference in the
proportion of hepatocytes that incorporated BrdUrd from 30
to 72 h after partial hepatectomy between these procedures
(Fig. 1A). At 36 h, which corresponds to the peak of DNA
replication after 2/3PH, the livers of mice with 2/3PH had
almost 10-fold higher levels of DNA replication compared
with animals with 1/3PH. The mitotic index determined 48 h
after hepatectomy was 5 times higher in 2/3PH mice com-
pared with 1/3PH animals (Fig. 1B). These data demon-
strated that, after a 1/3PH, there is lack of a robust synchro-
nous wave of DNA replication and that this procedure can
serve as a model for the analysis of incomplete regeneration.
Priming Phase Present after 1/3PH—To identify factors that
may be responsible for the incomplete regenerative response
after 1/3PH, we first examined the expression of a few repre-
sentative genes that are known to be highly expressed during
the priming phase that occurs during the first few hours after
partial hepatectomy. It is well established that c-jun, c-fos, and
c-myc are transiently expressed between 1 and 4 h after 2/3PH
as part of the immediate early gene response (20–22). RPA
analysis revealed that these three genes were similarly ex-
pressed in 1/3PH and 2/3PH from 30 min to 8 h post-surgery
(Fig. 2A and data not shown). We also found that the expres-
sion of genes that participate in the acute phase response, such
as IL-6 and SOCS-3, are similarly expressed after 1/3PH and
2/3PH (Fig. 2, B and C). These findings are in agreement with
and greatly extend a previous report that suggested that 1/3PH
can trigger a priming response (14), and it is consistent with
data from DNA microarray gene expression analyses in pro-
gress in the laboratory.2
Deficient G1/S Progression after 1/3PH—Cell cycle progres-
sion is regulated by the activity of complexes consisting of
cyclins, Cdks, and cyclin-dependent kinase inhibitors (23). It is
well established that Cdk-2 complexed with either cyclin E or A
cooperates with cyclin D-Cdk-4/6 to phosphorylate the Rb and
related p107 and p130 proteins. The phosphorylated proteins
release bound E2F transcription factor, which stimulates the
expression of genes required for S-phase (24). Therefore, we
analyzed the expression and activity of key regulators of the
G1/S transition from 24 to 48 h after 1/3PH compared with
2/3PH mice. First, we analyzed the expression of the Rb and of
p107, another member of the Rb family. In 2/3PH livers, the
phosphorylation of Rb was detected at 30 h after hepatectomy
and remained throughout the period of time studied (Fig. 3A).
In marked contrast, we could not detect phosphorylated Rb
after 1/3PH during the same period of time. The expression of
p107 was detectable but greatly diminished in 1/3PH (Fig. 3A).
We also analyzed the expression of p21, cyclin A, and cyclin D1
2 J. Li, C. Mitchell, J. Campbell, N. Fausto, and R. Bumgarner,
manuscript in preparation.
FIG. 2. Expression levels of immediate early genes. A, mRNA levels of c-jun and c-myc at different time points post-surgery as analyzed by
RPA (c-myc probe and custom probe set A). B, RPA gel of representative samples from 30 min to 8 h after 2/3PH (2), 1/3PH (1), or sham (S)
operations (custom probe set B). IFN-, interferon-; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; TNF-, tumor necrosis factor-. C,
quantification of mRNA levels of IL-6 and SOCS-3 analyzed by RPA (custom set B) at 4 h post-hepatectomy. The relative mRNA levels were
obtained by normalizing each sample against sham-operated mice (three animals were analyzed for each group).
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and cyclin E complexes, proteins associated with the G1/S tran-
sition. In 2/3PH, we detected cyclin A and p21 expression from
24/30 to 48 h (the last time point sampled in Fig. 3A). However,
in 1/3PH mice, the expression of these proteins was delayed,
diminished, and of shorter duration (Fig. 3A). The expression of
the Cdk-4/cyclin D1 complex was more robust and longer last-
ing in 2/3PH than in 1/3PH, even though the total levels of
cyclin D1 did not vary after either procedure (Fig. 3B). Finally,
the kinase activity associated with cyclin E increased only in
2/3PH mice (Fig. 3C). Altogether, these results showed that
there are well defined differences between 1/3PH and 2/3PH
regarding the expression of various cell cycle proteins. Whereas
2/3PH hepatocytes are clearly committed to proliferation be-
tween 24 and 48 h after the operation, at identical time points,
1/3PH hepatocytes do not exhibit protein expression patterns
characteristic of the G1/S transition.
HB-EGF Expression Increases prior to the G1-S Transition
in 2/3PH but is Not Changed in 1/3PH—Growth factors drive
cell cycle progression from early to late G1, at which time
replication becomes growth factor-independent (25). There-
fore, we examined the expression of growth factors from 12 to
36 h after 1/3PH and 2/3PH. The 12–24-h time period corre-
sponds to a phase that precedes the G1/S transition (see Fig.
1). We first examined, by RPA and real-time PCR, the liver
mRNA levels of the two main growth factors implicated in
liver regeneration, TGF- and HGF. TGF- mRNA levels
increased at 36 h only in 2/3PH mice (Fig. 4A), but there were
no obvious differences in HGF mRNA levels between 1/3PH
and 2/3PH at the time points examined (Fig. 4B). Given that
the expression of HGF and TGF- mRNA at 12–24 h after
hepatectomy (a period of time that precedes the G1/S transi-
tion) was similar in 1/3PH and 2/3PH, we determined
whether HB-EGF might be differentially expressed in these
two procedures. In 2/3PH, HB-EGF mRNA expression ap-
proximately doubled between 12 and 24 h after 2/3PH and
FIG. 3. Analysis of cell cycle proteins. A, Western blot analysis of
phospho-RB, p107, cyclin A, and p21 at different time points after
one-third (1) or two-thirds (2) partial hepatectomies. B, Western blot
analysis of cyclin D1 in samples previously immunoprecipitated with
Cdk-4 antibody or in total liver extracts at different time points after
one-third (1) or two-thirds (2) partial hepatectomies. -actin was used
as loading control for A and B. Sham animals (S) were killed 36 h
post-surgery. Each lane corresponds to a representative sample from
each group (n  3/group). C, densitometric quantification of cyclin
E-associated kinase activity at different time points post-hepatectomy
(n  3 animals/group).
FIG. 4. Growth factors expression levels after hepatectomy.
The mRNA levels of TGF- (A), HGF (B), and HB-EGF (C) were ana-
lyzed at different time points post-surgery. The HB-EGF and HGF
levels were assessed by RPA, and the levels of TGF- were assessed by
real-time PCR as described under “Material and Methods.” The relative
mRNA levels were obtained by normalizing each sample against sham-
operated mice (n  3 animals/group). *, p  0.05.
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returned to basal levels at 30 h (Fig. 4C). In marked contrast,
there was no increase in HB-EGF after 1/3PH. At 24 h after
partial hepatectomy, HB-EGF levels were 10-fold higher in
2/3PH compared with 1/3PH. Thus, the elevated HB-EGF
levels are correlated with liver regeneration and precede the
activation of cell cycle proteins. We conclude from these ex-
periments that HB-EGF might be a key factor in determining
cell cycle progression in regenerating liver and that its defi-
ciency could be associated with incomplete regeneration.
HB-EGF at a Low Dosage Stimulates DNA Replication in
1/3PH Mice—We compared the effects of small dosages of HB-
EGF, TGF-, and HGF in stimulating DNA synthesis in ani-
mals subjected to 30% hepatectomies. We gave a single injec-
tion of 0.1 mg/kg of each of these growth factors to 1/3PH mice
24 h after the surgery, and the animals were killed 12 h after
growth factor treatment. HB-EGF injection increased DNA
replication by 15-fold in 1/3PH mice but had little or no effect
in sham-operated animals (Fig. 5A). Moreover, DNA replica-
tion in 1/3PH mice injected with HB-EGF was 8-fold higher
than that of 1/3PH animals injected with either HGF or TGF-
(Fig. 5, A–D). These data demonstrate that HB-EGF triggers
DNA replication in 1/3PH mice at a dose in which HGF and
TGF- are without significant effects. Injections of any of the
growth factors into sham-operated mice had little effect on
hepatocyte DNA replication.
Liver Regeneration Is Delayed in HB-EGF Knock-out Mice—
Because of the large differential sensitivity to HB-EGF and
TGF- effects demonstrated in 1/3PH mice (Fig. 5) and the
earlier timing of the expression of HB-EGF during liver regen-
eration (Fig. 4C), we investigated whether HB-EGF knock-out
mice would have defects in liver regeneration. These knock-out
mice are viable and do not present abnormalities during liver
development or in non-injured livers. We performed 2/3PH in
HB-EGF knock-out mice and found that hepatocyte DNA rep-
lication in these animals was delayed and significantly lower at
30 and 36 h after partial hepatectomy compared with wild-type
mice (Fig. 6A). Despite its delayed onset, the levels of DNA
hepatocyte DNA replication in HB-EGF knock-out mice at 42
and 48 h after partial hepatectomy did not differ from the levels
in wild-type mice. To investigate whether other ligands of the
EGF family may compensate in part for the lack of HB-EGF in
the knock-out animals, we analyzed the expression of TGF-
and amphiregulin mRNAs in these animals. TGF- mRNA was
significantly increased at 24 h after 2/3PH in the knock-out
mice compared with wild-type animals (Fig. 6B), but there was
no difference in the expression of amphiregulin between wild-
type and knock-out animals after 2/3PH (data not shown). In
agreement with these findings, we detected a higher TGF-
protein expression at 36 h post-hepatectomy in the HB-EGF
knockouts compared with the wild-type mice (Fig. 6C). These
data indicate that the lack of HB-EGF does affect the kinetics
of liver regeneration and that increases in TGF- expression
may compensate for the absence of HB-EGF.
DISCUSSION
In the regeneration of the liver after partial hepatectomy,
hepatocytes that are normally quiescent cells enter the cell
cycle, replicate once or twice, and then return to quiescence.
Information obtained primarily in studies using genetically
modified mice support the view that regeneration is initiated
by a priming phase largely regulated by cytokines in which
hepatocytes undergo the G0/G1 cell cycle transition. During this
phase, which lasts approximately 4–6 h in regenerating mouse
liver, multiple genes are activated including several proto-
oncogenes. It is also well established that hepatocyte DNA
replication in the regenerating mouse liver does not start until
30 h after partial hepatectomy. Cell-cycle progression
through the G1 phase is driven primarily by two growth factors,
HGF and TGF-. In addition to its proliferative effects, HGF is
important for cell survival and motility, whereas TGF- is an
autocrine growth factor for hepatocytes and has mostly prolif-
erative effects. Despite the vast amount of information on the
role of cytokines and growth factors in liver regeneration, the
mechanisms that connect hepatocyte priming with cell cycle
progression are largely unknown.
To investigate these mechanisms, we compared some aspects
FIG. 5. Effect of growth factor (GF)
injection in DNA replication. Mice
were either submitted to 1/3PH or to
sham operation. 24 h later, they received
a bolus injection of 0.1 mg/kg HB-EGF,
TGF-, or HGF. The animals were killed
36 h post-surgery, and the livers were
analyzed by BrdUrd immunohistochemis-
try. A, quantification of BrdUrd incorpo-
ration in hepatocytes (n  3 animals/
group). **, p  0.01. The pictures show
BrdUrd immunostaining of animals hav-
ing received HB-EGF (B), TGF- (C), or
HGF (D) 24 h after 1/3PH (original mag-
nification, 100).
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of liver regeneration after 2/3PH, the standard procedure used
to elicit full synchronized liver regeneration, with 1/3PH, which
causes a delayed and asynchronous regenerative process (13,
19, 26). Using this approach, we established that the expres-
sion of HB-EGF, which occurs between 12 and 30 h after 2/3PH,
is critical for cell cycle progression and the G1/S transition in
the regenerating liver. Compared with 2/3PH mice, 1/3PH an-
imals had a very small replicative and mitotic response and
had defects in the expression of Rb and p107 and deficiencies in
the formation of cyclin/Cdk complexes. In these animals, the
expression of HB-EGF between 12 and 24 h after partial hep-
atectomy was 10-fold lower than that of 2/3PH mice.
Previous reports have shown that HB-EGF is expressed in
the regenerating liver before the hepatic expression of HGF
and TGF-, but it is not known whether HB-EGF is a crucial
player for the G1/S transition (11, 12). Injection of HB-EGF into
1/3PH mice 24 h post-PH resulted in a 15-fold increase in
DNA replication measured 12 h after the injection. In contrast,
the injection of HGF or TGF- at the same dosages failed to
elicit significant hepatocyte DNA replication. We have previ-
ously demonstrated that the continuous infusion of HGF and
TGF- for 24 h increases DNA replication in 1/3PH rats (14).
However, in this study, we gave a single injection of growth
factors at a specific time during liver regeneration and used a
lower dose of growth factors. The results indicate that, at 24 h
after partial hepatectomy, a period that precedes the G1/S
transition in 2/3PH mice, hepatocytes of 1/3PH mice are highly
sensitive to the proliferative effects of HB-EGF in comparison
with TGF- or HGF. The fact that an injection of TGF- did not
stimulate proliferation suggests that the mechanisms of induc-
tion of cell proliferation and the times at which hepatocytes are
particularly sensitive to a specific factor are not necessarily the
same for various ligands of the EGF family, even though HB-
EGF and TGF- share the same receptor (27). The differential
activity of these ligands may reflect differences in affinity or
prolonged binding for each ligand or be a consequence of
changes in the constitution of the EGF receptor dimer. How-
ever, no difference in the expression of EGF receptor 1, ErbB2,
and ErbB4 could be seen between 1/3PH and 2/3PH animals at
24 h after surgery (data not shown).
The importance of HB-EGF for liver regeneration is further
highlighted by the delay in DNA replication observed in HB-
EGF knock-out mice after 2/3PH. This result is particularly
significant because TGF- knock-out mice have no defects in
liver regeneration, an observation that may be due to redun-
dancy between the ligands of the EGF family. In HB-EGF
knock-out mice, there is an early increase in the expression of
TGF-, presumably as a compensation for the lack of HB-EGF.
Nevertheless, the early expression of TGF- is not sufficient to
overcome the defect caused by the lack of HB-EGF.
FIG. 6. Liver regeneration after 2/3PH in HB-EGF knock-out mice. A, DNA synthesis was analyzed by BrdUrd incorporation at different
times after two-thirds partial hepatectomy in HB-EGF knock-out (KO) or wild-type (WT) mice (4–7 animals/group were analyzed). B, the mRNA
levels of TGF- were analyzed at different time points post-surgery in these animals, and the relative mRNA levels were obtained by normalizing
each sample against non-operated control mice. *, p  0.05; **, p  0.01. C, Western blot analysis of TGF- (6-kDa form) and -actin at 36 h after
2/3PH in wild-type and HB-EGF knock-out animals.
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In summary, to uncover mechanisms that link the priming
phase of liver regeneration with hepatocyte DNA replication,
we used the model of 1/3PH, which differs from the standard
2/3PH by the lack of a clear wave of replication. These animals
have a defect in the expression of cell cycle genes that may be
attributed to the lack of expression of HB-EGF, a growth factor
that appears to play a key role in the induction of the G1/S
transition in the regenerating liver. The differential expression
of HB-EGF between 2/3PH and 1/3PH is consistent with data
showing that HB-EGF is not detectable in the serum of pa-
tients who underwent minor hepatectomies (subsegmentec-
tomy) but is present in the serum of patients with larger
hepatectomies (lobectomy or segmentectomy) (28).
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